Genetic Signatures Ltd.

As of June 30, 2026, Genetic Signatures Ltd. carries a market capitalization of 15.22M, placing it among publicly traded companies globally. Its enterprise value stands at -6.57M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Genetic Signatures Ltd.'s next confirmed earnings release is scheduled for February 16, 2027.

As of June 30, 2026, Genetic Signatures Ltd. has 227.14M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 1.05, and the price-to-book ratio stands at 0.43.

As of June 30, 2026, Genetic Signatures Ltd. maintains a current ratio of 13.10, meaning it holds 13.1x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Genetic Signatures Ltd. posted a negative return on equity (ROE) of -32.64, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -30.09, reflecting losses generated across the asset base. Inventory turnover of 1.24 indicates how many times Genetic Signatures Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 22, 2026, Genetic Signatures Ltd.'s stock has declined approximately 76.44% over the past 52 weeks. The 50-day moving average sits at 0.08, while the 200-day moving average is 0.10.

Over the twelve months ended June 30, 2026, Genetic Signatures Ltd. generated 14.45M in revenue and converted that into -14.01M in net income, yielding earnings per share of -0.06. EBITDA reached -17.76M, while operating income came in at -17.74M.

As of June 30, 2026, Genetic Signatures Ltd. holds 22.10M in cash and equivalents against 310,000.00 in total debt, resulting in a net debt position of -9.07M. Total book value stands at 35.72M, with working capital of 32.67M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Genetic Signatures Ltd. posted a gross margin of 34.52, reflecting its pricing power and cost economics. The operating margin of -122.76 and net profit margin of -96.91 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Total shareholder yield reaches 3.16, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Genetic Signatures Ltd. shareholders.

Genetic Signatures Ltd.'s most recent stock split took place on December 27, 2023 with a 42:43 split ratio.

As of June 30, 2026, Genetic Signatures Ltd. has an Altman Z-Score of -0.47, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.